Market Research Logo

Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SPRIX (ketorolac tromethamine) nasal spray for short-term management of moderate to moderately severe pain; and and Arymo ER (morphine sulfate) extended-release tablets C-II for chronic pain. The company develops products based on its proprietary Guardian technology, a polymer matrix tablet technology. Egalet is also developing pipeline of products using its Guardian Technology. It operates research facility, pilot manufacturing and administrative facility in Denmark. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp Key Recent Developments

Jun 07,2018: Egalet Names John Varian Board Director
May 08,2018: Egalet Reports First Quarter 2018 Financial Results
Mar 12,2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results
Nov 20,2017: Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian Technology
Nov 08,2017: Egalet Announces Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Egalet Corp - Key Facts
Egalet Corp - Key Employees
Egalet Corp - Key Employee Biographies
Egalet Corp - Major Products and Services
Egalet Corp - History
Egalet Corp - Company Statement
Egalet Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Egalet Corp - Business Description
R&D Overview
Egalet Corp - Corporate Strategy
Egalet Corp - SWOT Analysis
SWOT Analysis - Overview
Egalet Corp - Strengths
Egalet Corp - Weaknesses
Egalet Corp - Opportunities
Egalet Corp - Threats
Egalet Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Egalet Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 08, 2018: Egalet Reports First Quarter 2018 Financial Results
Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results
Nov 20, 2017: Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian Technology
Nov 08, 2017: Egalet Announces Third Quarter 2017 Financial Results
Aug 09, 2017: Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan
Jun 05, 2017: Egalet Announces Issuance of New U.S. Patent for Guardian Technology
May 10, 2017: Egalet Reports First Quarter 2017 Financial Results
Apr 10, 2017: Egalet Announces Changes to Board of Directors
Mar 09, 2017: Egalet Reports Fourth Quarter and Full Year 2016 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Egalet Corp, Key Facts
Egalet Corp, Key Employees
Egalet Corp, Key Employee Biographies
Egalet Corp, Major Products and Services
Egalet Corp, History
Egalet Corp, Other Locations
Egalet Corp, Subsidiaries
Egalet Corp, Key Competitors
Egalet Corp, Ratios based on current share price
Egalet Corp, Annual Ratios
Egalet Corp, Annual Ratios (Cont...1)
Egalet Corp, Interim Ratios
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Egalet Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Egalet Corp, Performance Chart (2013 - 2017)
Egalet Corp, Ratio Charts
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report